Abstract
Background: The present study analysed the impact of the integrated medical care of hydroxychloroquine (HCQ) and Siddha herbal preparation KSK on asymptomatic COVID-19 patients based on their body constitution.
Objective: The present study aimed to analyse the duration of the hospital stay of asymptomatic COVID-19 patients treated with the integrated medical care of hydroxychloroquine (HCQ) and herbal decoction of Kaba Sura Kudineer (KSK).
Design: The study included a retrospective case series of 19 asymptomatic confirmed SARS-Cov- -2 patients from District COVID Care Centre, Tirupati, India, between 23rd May to 7th June 2020.
Methods: Clinical data were collected using a standardised case report form containing demographic information, length of hospital stays, and Siddha Yakkai Ilakkanam (body constitution) from the records. The association between the length of hospital stay, age, gender, and Siddha YI for the confirmed patients after admission was analysed by the Kaplan Meier survival analysis method.
Results: Patients belonging to the Aiyam group stayed for at least nine days in the hospital, and 80% took ten or more days to cure the disease. About 71.4% took more than four days and three days of hospital stay in the Azhal and Vali groups, respectively. It was observed that 75% of females and 73.3% of males took nine days or more of hospital stay, respectively. The range of hospital stay was between 2-15 days for patients aged between 19 – 40 years.
Conclusion: The present study explored the significance of integrating Siddha medicine with Western medicine in the management of SARS Cov-2 infection. An overall median of 9 days in the length of stay and 8.5 days in the overall mean survival time was documented. The patients of the present study on integrative treatment recovered about nine days earlier in comparison to the patients studied in Vietnam and China.
Keywords: Body constitution, COVID-19, hydroxychloroquine, novel coronavirus, siddha medicine, yakkai ilakkanam.
Graphical Abstract
Current Traditional Medicine
Title:Survival Analysis Based on the Siddha Body Constitution of Asymptomatic SARS-CoV-2 Patients Under Integrative Management of Hydroxychloroquine (HCQ) and Kaba Sura Kudineer (KSK): A Retrospective Cross-sectional Case Series from Tirupati
Volume: 7 Issue: 6
Author(s): Samraj Karunanithi*, Sreenivasa Rao P, K Nandhagopal, Manoj Kumar D., N.P. Vinod, P. Sathyarajeswaran and K. Kanakavalli
Affiliation:
- Siddha Clinical Research Unit, Central Council for Research in Siddha, Tirupati,India
Keywords: Body constitution, COVID-19, hydroxychloroquine, novel coronavirus, siddha medicine, yakkai ilakkanam.
Abstract: Background: The present study analysed the impact of the integrated medical care of hydroxychloroquine (HCQ) and Siddha herbal preparation KSK on asymptomatic COVID-19 patients based on their body constitution.
Objective: The present study aimed to analyse the duration of the hospital stay of asymptomatic COVID-19 patients treated with the integrated medical care of hydroxychloroquine (HCQ) and herbal decoction of Kaba Sura Kudineer (KSK).
Design: The study included a retrospective case series of 19 asymptomatic confirmed SARS-Cov- -2 patients from District COVID Care Centre, Tirupati, India, between 23rd May to 7th June 2020.
Methods: Clinical data were collected using a standardised case report form containing demographic information, length of hospital stays, and Siddha Yakkai Ilakkanam (body constitution) from the records. The association between the length of hospital stay, age, gender, and Siddha YI for the confirmed patients after admission was analysed by the Kaplan Meier survival analysis method.
Results: Patients belonging to the Aiyam group stayed for at least nine days in the hospital, and 80% took ten or more days to cure the disease. About 71.4% took more than four days and three days of hospital stay in the Azhal and Vali groups, respectively. It was observed that 75% of females and 73.3% of males took nine days or more of hospital stay, respectively. The range of hospital stay was between 2-15 days for patients aged between 19 – 40 years.
Conclusion: The present study explored the significance of integrating Siddha medicine with Western medicine in the management of SARS Cov-2 infection. An overall median of 9 days in the length of stay and 8.5 days in the overall mean survival time was documented. The patients of the present study on integrative treatment recovered about nine days earlier in comparison to the patients studied in Vietnam and China.
Export Options
About this article
Cite this article as:
Karunanithi Samraj*, P Rao Sreenivasa, Nandhagopal K , D. Kumar Manoj , Vinod N.P. , Sathyarajeswaran P. and Kanakavalli K. , Survival Analysis Based on the Siddha Body Constitution of Asymptomatic SARS-CoV-2 Patients Under Integrative Management of Hydroxychloroquine (HCQ) and Kaba Sura Kudineer (KSK): A Retrospective Cross-sectional Case Series from Tirupati, Current Traditional Medicine 2021; 7 (6) : e100821195485 . https://dx.doi.org/10.2174/2215083807666210810113120
DOI https://dx.doi.org/10.2174/2215083807666210810113120 |
Print ISSN 2215-0838 |
Publisher Name Bentham Science Publisher |
Online ISSN 2215-0846 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Direct Targets and Subsequent Pathways for Molecular Hydrogen to Exert Multiple Functions: Focusing on Interventions in Radical Reactions
Current Pharmaceutical Design The Recovery of an Elderly Woman with Asthma and Diabetes from COVID-19 Infection: A Case Report
Infectious Disorders - Drug Targets Medicinal Importance, Pharmacological Activities and Analytical Aspects of a Flavonoid Glycoside ‘Nicotiflorin’ in the Medicine
Drug Metabolism and Bioanalysis Letters Structural Genomics and Drug Discovery for Infectious Diseases
Infectious Disorders - Drug Targets Prevention and Management of SARS-CoV-2 Infection Among the Health Care Workers
Coronaviruses Coordinated Roadmap to Grip Pandemic COVID-19
Coronaviruses Binding of CYP2C9 with Diverse Drugs and its Implications for Metabolic Mechanism
Medicinal Chemistry RNA Interference with Chemically Modified siRNA
Current Topics in Medicinal Chemistry Modifications of Medical Care of Chronic Liver Diseases During COVID-19 Pandemic: Necessity or Novelty?
Infectious Disorders - Drug Targets Chimeric Virus-like Particles of Universal Antigen Epitopes of Coronavirus and Phage Qβ Coat Protein Trigger the Production of Neutralizing Antibodies
Current Topics in Medicinal Chemistry Does Metformin Satisfy as an Option for Host-Directed Therapy in COVID-19?
Anti-Infective Agents The Role of Nanoparticles as Nanocarriers for the Controlled Release of some Potential Existing Antiviral Drugs for SARS-CoV-2 Management: A Review
Coronaviruses Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report
Infectious Disorders - Drug Targets 2019 Novel Coronavirus: A Review on Epidemiology, Pathophysiology, Diagnosis and Current Clinical Trials in Vaccine Development
Coronaviruses Transmission Modes of COVID-19: A Systematic Review
Infectious Disorders - Drug Targets Pleural Effusion as a Sign of Coronavirus Disease 2019 (COVID-19) Pneumonia: A Case Report
Infectious Disorders - Drug Targets Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part-I)
Current Pharmaceutical Design Impact and Inescapable Effects of Coronavirus: History to Modern Pandemic Episode
Coronaviruses Knowledge Evaluation of Hand Hygiene and Infectious Diseases in Lebanon
Coronaviruses Recent Developments in the Virology and Antiviral Research of Severe Acute Respiratory Syndrome Coronavirus
Infectious Disorders - Drug Targets